Steffen Spoerl1, Michael Gerken2, René Fischer3, Andreas Mamilos4, Silvia Spoerl5, Stefanie Wolf6, Fabian Pohl7, Christoph Klingelhöffer1, Tobias Ettl1, Torsten E Reichert1, Gerrit Spanier8. 1. Department of Cranio-Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany. 2. Tumor Center - Institute for Quality Management and Health Services Research, University of Regensburg, Regensburg, Germany. 3. Department of Otorhinolaryngology, University Hospital Regensburg, Regensburg, Germany. 4. Institute of Pathology, University Regensburg, Regensburg, Germany. 5. Department of Internal Medicine 5 - Hematology/Oncology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. 6. Department of Otorhinolaryngology, St. Elisabeth Hospital Straubing, Straubing, Germany. 7. Department of Radiation Oncology, University Hospital Regensburg, Regensburg, Germany. 8. Department of Cranio-Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany. Electronic address: gerrit.spanier@ukr.de.
Abstract
OBJECTIVE: Numerous studies analyzed lymphovascular invasion (LVI) in various malignant diseases, however, little is known about the role of lymphatic invasion (LI) as well as vascular invasion (VI) in oral squamous cell carcinoma (OSCC). The aim of this study is to illuminate the role of LI and VI in a population-based cohort study. METHODS: We retrospectively analyzed 745 primarily resected OSCC patients in Eastern Bavaria for histopathologically verified LI and VI. Overall survival (OS) and recurrence-free survival (RFS) were calculated, whereas analysis was performed by uni- and multivariate statistics. Mean follow-up time was 7.4 years. RESULTS: LI was found in 115 patients (15.4%), VI was diagnosed in 23 cases (3.1%). LI correlated significantly with distinct anatomical sites (p = 0.004), increasing pT-classification (p < 0.001), lymph node involvement (p < 0.001), higher grading (p < 0.001), advanced UICC-stages (p < 0.001) and adjuvant therapies (p < 0.001). Similar results were found for VI. Survival analysis resulted in a significantly decreased five-year OS and RFS in patients with diagnosed LI (OS: 41.1%, RFS: 38.3%) in contrast to LI-negative cases (OS: 66.8%, RFS: 59.7.7%, p < 0.001). Analogous outcomes were seen for patients with VI. Additionally, LI was identified as a predictive parameter, indicating individual patients' response to adjuvant therapies. CONCLUSION: This population-based cohort study underlines the unfavorable aspect of LI and VI on outcome in OSCC. Including LI and VI in existing staging systems could help to stratify patients' risk for adverse outcome and consecutively determine adjuvant treatment in malignant disease.
OBJECTIVE: Numerous studies analyzed lymphovascular invasion (LVI) in various malignant diseases, however, little is known about the role of lymphatic invasion (LI) as well as vascular invasion (VI) in oral squamous cell carcinoma (OSCC). The aim of this study is to illuminate the role of LI and VI in a population-based cohort study. METHODS: We retrospectively analyzed 745 primarily resected OSCC patients in Eastern Bavaria for histopathologically verified LI and VI. Overall survival (OS) and recurrence-free survival (RFS) were calculated, whereas analysis was performed by uni- and multivariate statistics. Mean follow-up time was 7.4 years. RESULTS: LI was found in 115 patients (15.4%), VI was diagnosed in 23 cases (3.1%). LI correlated significantly with distinct anatomical sites (p = 0.004), increasing pT-classification (p < 0.001), lymph node involvement (p < 0.001), higher grading (p < 0.001), advanced UICC-stages (p < 0.001) and adjuvant therapies (p < 0.001). Similar results were found for VI. Survival analysis resulted in a significantly decreased five-year OS and RFS in patients with diagnosed LI (OS: 41.1%, RFS: 38.3%) in contrast to LI-negative cases (OS: 66.8%, RFS: 59.7.7%, p < 0.001). Analogous outcomes were seen for patients with VI. Additionally, LI was identified as a predictive parameter, indicating individual patients' response to adjuvant therapies. CONCLUSION: This population-based cohort study underlines the unfavorable aspect of LI and VI on outcome in OSCC. Including LI and VI in existing staging systems could help to stratify patients' risk for adverse outcome and consecutively determine adjuvant treatment in malignant disease.
Authors: Jonas Eichberger; Florian Weber; Gerrit Spanier; Michael Gerken; Stephan Schreml; Daniela Schulz; Mathias Fiedler; Nils Ludwig; Richard Josef Bauer; Torsten Eugen Reichert; Tobias Ettl Journal: Cancers (Basel) Date: 2022-08-22 Impact factor: 6.575